Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
deltaEF1 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
deltaEF1 siRNA is a small interfering RNA (siRNA) designed to target and knock down the expression of deltaEF1 (also known as zinc finger E-box-binding homeobox 1, ZEB1, or TCF8). deltaEF1 is a zinc finger-homeodomain transcription factor that acts as a key regulator of epithelial-to-mesenchymal transition (EMT), cell proliferation, and differentiation. In research settings, deltaEF1 siRNA is utilized as a laboratory tool to investigate the role of deltaEF1 in various biological processes and diseases, particularly in breast cancer and other malignancies where deltaEF1 overexpression is associated with tumor progression, metastasis, and drug resistance. Knockdown of deltaEF1 using this siRNA has been shown to inhibit cell proliferation, induce cell cycle arrest, and restore sensitivity to therapeutic agents in vitro.
- Other names
- AREB6 siRNAAREB-6 siRNAAREB 6 siRNATCF8 siRNATCF-8 siRNATCF 8 siRNAZEB1 siRNAZEB-1 siRNAZEB 1 siRNAdelta-crystallin enhancer-binding factor 1 siRNAdeltaEF1 siRNAdeltaEF-1 siRNAdeltaEF 1 siRNAsiRNA-AREB6siRNA-AREB-6siRNA-AREB 6siRNA-TCF8siRNA-TCF-8siRNA-TCF 8siRNA-deltaEF1siRNA-deltaEF-1siRNA-deltaEF 1siRNA-ZEB1siRNA-ZEB-1siRNA-ZEB 1
02
Targets
AGO2 (Argonaute RISC catalytic component 2)CDH1 (Cadherin-1)ZEB1 (Zinc finger E-box-binding homeobox 1)
Beyond the preview
Go deeper on deltaEF1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on deltaEF1 siRNA.